New drug CKD-508 tested for safety in healthy people
NCT ID NCT06727396
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and how the body handles CKD-508, a new drug, in 44 healthy adults. Participants received either the drug or a placebo once daily. The study measured side effects, drug levels in the blood, and changes in cholesterol-related markers. Since this is a Phase 1 study in healthy people, it does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CKD-508 tablet
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Glendale, California, 91206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer reveals the Body's journey of an experimental drug
- Can music lessons rewire Teens' social media habits?
- Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Sound waves as medicine: ultrasound may tame inflammation without drugs
- Broader pneumonia shield: new vaccine tested in children